GPT and neutropenia: Grade 3–4 AEsPembrolizumab + axitinib: 76% (most common: hypertension [22%]; increased ALT [13%); diarrhoea [9%]; increased AST [7%]; PPES [5%])Sunitinib: 71% (most common: hypertension [19%]; decreased neutrophils [7%]; neutropenia [7%]; fatigue [7%]; thrombocytopenia [6%]; decreased platelets [7%])